African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
myeloma
outcomes
race
t(11;14)
transplant
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
23
03
2020
revised:
07
05
2020
accepted:
13
06
2020
pubmed:
24
9
2020
medline:
8
9
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent. This study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187). African Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI). Fewer African Americans with t(11;14) (21%) had a coexistent high-risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression-free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P = .03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT-CI, and receipt of maintenance. Race may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.
Sections du résumé
BACKGROUND
Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent.
METHODS
This study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187).
RESULTS
African Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI). Fewer African Americans with t(11;14) (21%) had a coexistent high-risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression-free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P = .03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT-CI, and receipt of maintenance.
CONCLUSIONS
Race may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.
Identifiants
pubmed: 32966625
doi: 10.1002/cncr.33208
pmc: PMC7736245
mid: NIHMS1630806
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-92Subventions
Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL141445
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168762
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL069294
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215134
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128775
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069197
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218285
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130388
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2020 American Cancer Society.
Références
Eur J Haematol. 2018 Feb;100(2):215-217
pubmed: 29064593
Mayo Clin Proc. 2013 Apr;88(4):360-76
pubmed: 23541011
Blood Cancer J. 2018 Oct 10;8(10):96
pubmed: 30305608
Bone Marrow Transplant. 2006 Jun;37(12):1099-102
pubmed: 16699527
Am J Hematol. 2008 May;83(5):355-8
pubmed: 18186525
Blood. 2016 Jul 28;128(4):594-602
pubmed: 27257181
Leukemia. 2018 Jan;32(1):131-138
pubmed: 28655925
N Engl J Med. 2004 Oct 28;351(18):1860-73
pubmed: 15509819
Nat Rev Cancer. 2002 Mar;2(3):175-87
pubmed: 11990854
JAMA Oncol. 2018 Mar 1;4(3):343-350
pubmed: 29302684
Blood Cancer J. 2019 Feb 4;9(2):15
pubmed: 30718460
N Engl J Med. 2012 May 10;366(19):1770-81
pubmed: 22571201
Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421
pubmed: 28606646
Biol Blood Marrow Transplant. 2013 Aug;19(8):1227-32
pubmed: 23733001
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Biol Blood Marrow Transplant. 2010 Mar;16(3):395-402
pubmed: 19922808
Biol Blood Marrow Transplant. 2015 Apr;21(4):701-6
pubmed: 25555447
Blood. 2007 Apr 15;109(8):3489-95
pubmed: 17209057
Cancer. 2010 Jul 15;116(14):3469-76
pubmed: 20564154
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35
pubmed: 25812994
Nat Rev Clin Oncol. 2018 Jul;15(7):409-421
pubmed: 29686421
Cancer. 2017 Aug 15;123(16):3141-3149
pubmed: 28472539
Blood. 2002 May 15;99(10):3735-41
pubmed: 11986230
Lancet Haematol. 2017 Sep;4(9):e431-e442
pubmed: 28826616
Leukemia. 2016 Mar;30(3):633-9
pubmed: 26487275
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Cancer Metastasis Rev. 2003 Mar;22(1):87-93
pubmed: 12716040